Hämostaseologie, Table of Contents Hamostaseologie 1983; 03(03): 97-101DOI: 10.1055/s-0038-1656624 Originalarbeiten Schattauer GmbH Die Rolle der Prostaglandine in der Entstehung von Gefäßveränderungen bei Diabetikern Authors Author Affiliations H. Sinzinger * 1 Aus der Abteilung für Nuklearmedizin an der II. Medizinischen Universitätsklinik und Atheroskleroseforschungsgruppe (ASF) am Institut für Medizinische Physiologie der Universität Wien, Österreich Recommend Article Abstract Buy Article(opens in new window) Full Text References LITERATUR 1 Auerswald W, Sinzinger H. Altersabhängiges Verhalten der Plättchensensitivität für antiaggregatorische Prostaglandine. Wr. Tierärztl. Mschr 1981; 68: 332-335. 2 Axelrod L, Levine L. Plasma prostaglandin levels in rats with diabetes mellitus and diabetic ketoacidosis. Diabetes 1982; 31: 994-1001. 3 Betteridge D. J, El Tahir K. E. H, Reckless J. P. D, Williams K. I. Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Europ. J. Clin. Invest 1982; 12: 395-398. 4 Coughlin S, Meshkowitz M. A, Zetter B. R, Antoniades H. N, Levine L. Platelet dependent stimulation of prostacyclin synthesis by platelet derived growth factor. Nature 1981; 288: 600-603. 5 Davis T. M. E, Mitchell M. D, Dornan T. L, Turner R. C. Plasma 6-keto-PGF1alpha concentrations and diabetic retinopathy. Lancet 1980; I: 373 6 Davis T. M. E, Mitchell M. D, Turner R. C. Prostacyclin and thromboxane metabolites in diabetes. Lancet 1980; I: 789-790. 7 Dollery C. T, Friedman L. A, Hensby C. N, Kohner E, Lewis P. J, Porta M, Webster J. Circulating prostacyclin may be reduced in diabetes. Lancet 1979; II: 1365 8 Garcia-Conde H, Amado J. A, Merino J, Bluet J. Prostaglandins and platelet function in diabetes. Thromb. Haemost 1979; 42: 789 9 Gryglewski R. J, Szczeklik A. Prostacyclin and atherosclerosis. In Lewis P. J, O’Grady J. Clinical Pharmacology of Prostacyclin Raven Press; New York: 1981: 89-95. 10 Halushka P. V, Rogers P. C, Loadholt C. B, Colwell J. A. Increased platelet thromboxane A2 biosynthesis in diabetes mellitus. J. Lab. Clin. Med 1981; 97: 87-96. 11 Hamberg M, Svensson J, Samuelson B. Thromboxane: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Nat. Acad. Sci. USA 1975; 72: 2294-2298. 12 Harrison H. E, Reece A. H, Johnson M. Decreased vascular prostacyclin in experimental diabetes. Life Sciences 1978; 23: 351-356. 13 Harrison H. E, Reece A. J, Johnson M. Effect of insulin treatment on prostacyclin in experimental diabetes. Diabetologia 1980; 18: 65-68. 14 Hope W, Chesterman G. J, Dusting G. J, Smith F. J, Morgan I, Martin T. J. Inhibition by ß-thromboglobulin of prostacyclin (PGI2) formation in arterial endothelial cells. Thromb. Haemost 1979; 42: 8 15 Johnson M, Harrison H. E, Raftery A. T, Elder J. B. Vascular prostacyclin may be reduced in diabetes in man. Lancet 1979; I: 325-326. 16 Johnson M, Reece A. H, Harrison H. E. Decreased vascular prostacyclin in experimental diabetes. Adv. Pharmacol. Chemother 1979; a 4: 856-869. 17 Johnson M, Reece A. M, Harrison H. E. An imbalance in arachidonic acid metabolism in diabetes. Adv. Prostagl. Thromb. Res 1980; 8: 1283-1286. 18 Johnson M, Reece A. H, Harrison H. E. An imbalance in arachidonic acid metabolism in human and experimental diabetes. Artery 1980; a 6: 81-86. 19 Johnson M, Harrison H. E, Raftery A. T, Elder J. B. Prostacyclin and diabetes. In Lewis P. J, O’Grady J. Clinical Pharmacology of prostacyclin Raven Press; New York: 1981: 105-112. 20 Karpen C. W, Pritchard K. A, Arnold J. H, Cornwell D. G, Panganamala R. V. Restoration of prostacyclin/thromboxane A2 balance in the diabetic rat: influence of dietary vitamin E. Diabetes 1982; 31: 947-951. 21 Klein K, Kaliman J, Sinzinger H, Silberbauer K. Plättchensensitivität für Prostacyclin bei diabetischen und nicht-diabetischen Patienten mit atherosklerotischen Gefäßveränderungen – ein Maß für die Prostaglandinrezeptoren. VASA 1980; 9: 123-129. 22 Leithner Ch, Winter M, Silberbauer K, Wagner O, Pinggera W. F, Sinzinger H. Enhanced prostacyclin availability from blood vessels in uremic humans and rats. Proc. EDTA 1978; 12: 418-422. 23 MacIntyre D. E, Pearson J. D, Gordon J. L. Localization and stimulation of prostacyclin production in vascular cells. Nature 1978; 271: 549-551. 24 Marks H. H, Krall L. P. Onset, course, prognosis and mortality in diabetes mellitus. In Marble A, White P, Pradley R. F, Krall L. P. Joslin’s Diabetes mellitus Lea & Febiger; 1971: 186 ff 25 Moncada S, Gryglewski R. J, Bunting S, Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-665. 26 Moncada S, Higgs E. A, Vane J. R. Human arterial and venous rings generate prostacyclin a potent inhibitor of platelet aggregation. Lancet 1977; I: 18-21. 27 Ondodeva H, Hirata T, Sugawara H, Sugai K, Yoda B, Toyota T, Goto Y. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients. Tohoku J. exp. Med 1982; 137: 423-428. 28 Ross R, Glomset J. A. The pathogenesis of atherosclerosis. The New Engl. J. Med 1976; 295: 369-377. 29 Schernthaner G, Silberbauer K, Sinzinger H, Müller M. Plasma ß-thromboglobulin and glycosylated hemoglobin in type I and type II diabetes mellitus. Thromb. Haemost 1979; 42: 334 30 Schernthaner G, Sinzinger H, Silberbauer K, Freyler H. Altered platelet funtion in diabetes mellitus. Decrease of vascular prostacyclin, analysis of plasma ß-thromboglobulin and platelet factor 4 according to state of metabolic control and diabetic microangiopathy stages. In Tesi M. 1st Int. Coll. Angiology Academic Press; New York – London: 1980: 277ff 31 Schrör K, Rösen P. Increased prostacyclin release from perfused hearts of acutely diabetic rats. Diabetologia 1980; 61: 391-394. 32 Siegl A. M, Smith J. B, Silver M. J, Nicolaou K. C, Ahern D. Selective binding site for 3H-prostacyclin on platelets. J. Clin. Invest 1979; 63: 215-223. 33 Silberbauer K, Schernthaner G, Sinzinger H, Piza-Katzer H, Winter M. Decreased vascular prostacyclin in juvenile-onset diabetes. The New Engl. J. Med 1979; 300: 366-367. 34 Silberbauer K, Sinzinger H, Winter M. Prostacyclin activity in rat kidney stimulated by angiotensin II. Brit. J. exp. Pathol 1979; 60: 38-44. 35 Silberbauer K, Schernthaner G, Sinzinger H, Clopath P, Piza-Katzer H, Winter M. Diminished prostacyclin generation in human and experimentally induced (streptozotocin, alloxan) diabetes mellitus. Thromb. Haemost 1979; 42: 334 36 Sinzinger H, Silberbauer K, Winter M. Prostacyclin formation by vascular smooth muscle cells. Lancet 1978; I: 1352-1353. 37 Sinzinger H, Silberbauer K, Auerswald W. Prostacyclin formation by human vascular wall. Atherosclerosis 1979; V: 140-143. 38 Sinzinger H, Silberbauer K, Oppolzer R, Winter M, Auerswald W. Prostacyclin (PGI2)-generation by different types of human atherosclerotic lesions. Exp. Pathol 1980; 18: 175-178. 39 Sinzinger H, Silberbauer K, Clopath P, Schernthaner G. Effect of experimentally induced diabetes on swine vascular prostacyclin (PGI2) synthesis. Artery 1981; 8: 30-36. 40 Sinzinger H, Auerswald W. Temporary increase in vascular prostacyclin in experimental diabetes. Proc. Acad. Sci 1981; 26: 24-35. 41 Sinzinger H, Schernthaner G, Kaliman J. Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prostaglandins 1982; 22: 773-781. 42 Sinzinger H, Kaliman J, Kefalides A, Christa Hoche, Peskar B. A. The prostacyclin synthesis stimulating plasma factor is unchanged in acute angina pectoris. im Druck 1983 43 Sinzinger H. W. Firbas: Gefäßwandzellen synthetisieren Thromboxan. Wr. Klin. Wschr. (in press). 1983 44 Webster J. M. Porta, Hensby C. N, Kohner E. M, MacDermot J, Lewis P. J. Plasma levels of 6-oxo-PGF1alpha, the hydrolysis product of prostacyclin may be reduced in diabetes. In Lewis P. J, O’Grady J. Clinical Pharmacology of prostacyclin 113-116. Raven Press; New York: 1981 45 Ziboh V. A, Maruta H, Lord J, Cagel W. D, Lucky W. Increased biosynthesis of thromboxane A2 by diabetic platelets. Europ. J. Clin. Invest 1979; 9: 223-228.
